Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Melanoma, Brain Metastases
Interventions
nab-paclitaxel, Temozolomide, Bevacizumab
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Tucson, Arizona
Conditions
Metastatic Melanoma
Interventions
MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional Accepts healthy volunteers

In Vivo Liquid Biopsy of Melanoma (Cytophone)

NCT06488365
Conditions
Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
Interventions
Cytophone
Device
Lead sponsor
Cytoastra
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Melanoma
Interventions
YM155
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Tuscon, Arizona • Little Rock, Arkansas • Aurora, Colorado + 6 more
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more
Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Skin Carcinoma
Interventions
Best Practice, Educational Intervention, Electronic Health Record Review, Follow-Up Care, Medical Device Usage and Evaluation, Negative Pressure Wound Therapy, Photography, Questionnaire Administration
Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
752
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more
Conditions
Melanoma
Interventions
AZD6244, Temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Santa Monica, California • Aurora, Colorado • Miami Beach, Florida + 7 more
Conditions
Melanoma, Malignant Melanoma, Metastatic Melanoma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Grand Rapids, Michigan • New York, New York • Dallas, Texas
Conditions
Melanoma, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Troriluzole, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Melanoma
Interventions
Nivolumab + Relatlimab, rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more
Conditions
Cutaneous Melanoma
Interventions
Not listed
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
16 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Santa Rosa, California • Frederick, Maryland • Las Vegas, Nevada + 1 more
Conditions
Melanoma
Interventions
Decitabine, Pegylated Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma (Skin)
Interventions
boron neutron capture therapy
Radiation
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ixabepilone, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Melanoma
Interventions
radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
39
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Joliet, Illinois + 22 more
Conditions
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Interventions
Information collection
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more
Conditions
Locally Advanced Unresectable or Metastatic Melanoma
Interventions
Selinexor, Pembrolizumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more
Conditions
Melanoma
Interventions
LGX818
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-small Cell Lung Cancer, Melanoma
Interventions
IMM60, Pembrolizumab
Drug
Lead sponsor
iOx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Conditions
Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions
Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Interventions
KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas